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Abstract  
Background 
Economic evaluations of healthcare interventions increasingly measure outcomes using 
quality-adjusted life years (QALYs). The SF-6D and the EQ-5D are alternative ways of 
generating utility scores for use in QALY estimations, but it is unclear which is most sensitive 
to change in psychiatric symptom severity. There are also limited data on the sensitivity of 
these measures to changes in existing clinical indicators in long-term mental health conditions 
like schizophrenia. 
Aims of the study 
To: (i) assess the relationship between SF-6D and EQ-5D utility scores for patients with 
schizophrenia at two points in time, (ii) assess the relationship in the change scores of these 
two measures, (iii) measure the sensitivity of these measures to changes in an established 
measure of symptomatology. 
Methods 
Patients with schizophrenia were recruited and the SF-36 and EQ-5D were administered at 
baseline and one-year follow-up and utility scores were computed and compared.. 
Standardised response mean (SMR) scores were calculated for the SF-6D and EQ-5D and 
compared for patients who improved or deteriorated by at least 25% on the Brief Psychiatric 
Rating Scale. 
Results 
EQ-5D ratings were available for 394 patients at baseline, 368 at follow-up and 358 at both 
time points. The respective figures for the SF-6D were 383, 367 and 345. Mean utility scores 
were very similar at baseline (EQ-5D 0.68, SF-6D 0.67) and follow-up (EQ-5D 0.71, SF-6D 
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0.68). Median scores were markedly higher for the EQ-5D (0.76 v 0.66 at baseline, 0.80 v 
0.68 at follow-up). The SF-6D scores followed a normal distribution whilst the EQ-5D scores 
were negatively skewed with a clustering at 1.00. There were few differences in sensitivity to 
change between the EQ-5D and SF-6D. 
Discussion 
From an analytical perspective the SF-6D has advantages over the EQ-5D due to its normal 
distribution and lack of ceiling effect. However, both measures produce similar mean utility 
scores. Overall the SF-6D appears more suitable as a measure if utility in this patient group. 
 
Implications for health policies 
Decisions made on the basis of cost-effectiveness results need to consider the method by 
which QALYs have been calculated. 
 
Implications for further research 
Further comparisons of the EQ-5D and SF-6D are required. 
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Introduction 
 
Deciding which outcome measures are to be used in economic evaluations is important for the 
purposes of making policy decisions, and different measures can produce very different 
findings [1]. As well as condition specific measures, studies frequently use generic measures 
of health-related quality of life or health status in order to estimate quality-adjusted life years 
(QALYs) and the cost per QALY gained from one intervention compared to another. 
Alternative ways of estimating QALY weights exist, including the standard gamble and the 
time trade-off methods [2]. These can be complex to carry out within a trial and a common 
solution is to use a multi-attribute scale, which defines specific health states to which existing 
utility weights can be attached. The EuroQol/EQ-5D instrument is one such scale and has 
been used in numerous evaluations [3]. An alternative is the SF-6D, which is based on the SF-
36 and is growing in popularity [4].  
 
The sensitivity of utility scores derived from the EQ-5D and SF-6D to change in different 
disorders is unclear. In mental health there is concern over the use of such measures [5]. One 
of the likely limitations of existing QALY measures is their large focus on physical health 
problems. By concentrating on physical health it becomes much more of a challenge for 
mental health interventions to achieve a particular QALY gain compared with interventions 
for other conditions. This in turn could result in artificially high cost-utility ratios for mental 
health interventions. In the extreme case this could mean that resources are diverted away 
from mental health care by decision makers simply as a result of insensitive QALY measures. 
It is therefore crucial to ascertain whether these measures are sensitive to change in mental 
health and this paper seeks to compare the use of the EQ-5D and SF-6D using data from an 
evaluation of interventions for schizophrenia.  
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The specific aims of this study are to: (i) assess the relationship between SF-6D and EQ-5D 
utility scores for patients with schizophrenia at two points in time, (ii) assess the relationship 
in the change scores of these two measures, and (iii) measure the sensitivity of these measures 
to changes in an established measure of psychiatric symptoms. 
 
Schizophrenia frequently follows a chronic course, and often results in high levels of 
disability [6], and this may well have an impact on quality of life. A small number of studies 
have examined the use of the EQ-5D in patients with schizophrenia, but few have assessed its 
validity [7]. We are not aware of any evaluations in schizophrenia that have used the SF-6D. 
Different methods of measuring utility can produce very different results [8] and it is 
important, therefore, to select the most suitable instrument. To inform this decision it is 
helpful to compare the sensitivity to change of different measures and this paper seeks to do 
this for the EQ-5D and SF-6D. One study has compared these two measures for patients with 
mood and anxiety disorders [9]. This found that both instruments were sensitive to differences 
in symptom severity but that the EQ-5D showed greater health gains. The study here uses 
similar methods but examines the use of the EQ-5D and SF-6D for a condition which is more 
severe and for which cost-utility analyses may be less easy to conduct. 
 
 
Methods 
 
Data for this study were collected as part of a multi-site European study which compared the 
impact that medication adherence therapy and a health education intervention for 
schizophrenia had on quality of life (the QUATRO study). Details of the study are provided 
elsewhere [10]. Patients with schizophrenia were recruited from the Netherlands, Germany, 
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the UK and Italy and were randomised to receive one of the two interventions. For inclusion, 
a clinical diagnosis of schizophrenia was confirmed using the Item Group Checklist of the 
Schedule for Clinical Assessment in Neuropsychiatry [11]. Recruitment was from general 
adult psychiatric settings (community and inpatient). A number of measures were taken at 
baseline and one-year follow-up and of particular relevance to the analyses presented here 
were the EQ-5D [3], the SF-36 [12] (which was the primary outcome measure in the clinical 
trial) and the 24-item Brief Psychiatric rating Scale (BPRS) [13]. Disability was measured 
with the Global Assessment of Functioning (GAF) [14]. 
 
The EQ-5D is a five dimensional questionnaire, the dimensions being mobility, self-care, 
usual activities, pain/discomfort and depression/anxiety. Each of these dimensions can be 
rated as 1 (no problem), 2 (some problem) or 3 (major problem). There are 243 distinct health 
states produced by the EQ-5D, and in the UK a sample of these have been valued by a 
community sample using the time trade-off method, with regression analyses used to estimate 
utility values for the remaining states [15].  
 
Brazier and colleagues developed the SF-6D from the SF-36 [4]. The original instrument was 
reduced to six items (physical functioning, role limitations, social functioning, pain, mental 
health, vitality) each of which has between two and six levels of severity. This resulted in a 
total of 18,000 different health states and a sample of 249 of these were rated among 611 
members of a community sample using the standard gamble method in order to generate 
preference-based utility scores. As with the EQ-5D, regression models were used to estimate 
utility scores for the remaining health states. 
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The BPRS is one of the most frequently used measures of psychiatric symptomatology. The 
expanded 24-item scale was used. This is an interviewer administered instrument and contains 
items relating to psychiatric symptoms during the past two weeks and also symptoms shown 
during the interview. Each item is rated between one (symptom not present) and seven 
(extremely severe symptom). A total score is obtained by summing scores for individual 
items, and a higher score indicates worse problems. This version of the BPRS has been 
demonstrated to have good inter-rater reliability [16] and to be sensitive to change [17]. 
Furthermore, Ruggeri et al have identified a common component structure for the instrument 
across five European sites (including three that are also included here) [18]. 
 
Data analytic procedures 
EQ-5D and SF-6D utility scores (using UK weights) were computed and compared, with 
paired t-tests and the Wilcoxon test of differences in the mean ranks of observations used to 
identify significant differences (defined as p<0.05). Spearman’s correlations were computed 
for both baseline and follow-up scores, and also for the change scores in both measures 
between the two time points. 
 
Spearman’s correlations that the EQ-5D and SF-6D had with the BPRS at baseline were 
computed. The sensitivity of the EQ-5D and SF-6D to changes in the BPRS was assessed by 
generating a Spearman’s correlation of the change scores. In addition, we estimated 
standardised response mean (SRM) scores for the EQ-5D and  SF-6D for patients who 
improved or deteriorated by at least 25% or on the BPRS. SRMs are similar to effect sizes and 
defined as the change between baseline and follow-up divided by the standard deviation of 
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this change [19]. Whilst any cut-off point is somewhat arbitrary, 25% is likely to represent 
minimal change on the BPRS that is clinically important [20].  
 
 
Results 
 
A total of 409 patients were randomised. There were slightly more men than women and 
three-quarters were White European (Table 1). Around one-third of the sample had been 
admitted to hospital during the previous year. The data on duration of time on neuroleptics 
and the GAF score indicate the chronicity and high disability of the sample. The mean 
(median) follow-up period was 373 (368) days with a range of 287-629. Complete EQ-5D 
ratings were available for 394 patients at baseline, 368 at follow-up and 358 at both time 
points. The respective figures for the SF-6D were 383, 367 and 345.  
 
The mean EQ-5D and SF-6D utility scores were similar at both baseline and follow-up (Table 
2). The difference of 0.01 in mean utility scores at baseline was not statistically significant 
(p=0.420). The difference at follow-up was 0.03 and this was significant (p=0.030). However, 
this difference is small and may not be clinically important. The median scores were 
substantially higher for the EQ-5D and the Wilcoxon test revealed that the distributions were 
significantly different at baseline (p=0.001), as can clearly be seen from Figures 1 and 2. 
Follow-up distributions (not shown) revealed similar differences (p<0.001). Variation as 
measured by the standard deviation was noticeably greater for the EQ-5D, and this is also 
shown by the range in scores. The median score for the SF-6D was similar to the mean, whilst 
for the EQ-5D it was higher. This indicates greater skewness in the EQ-5D scores than those 
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from the SF-6D. Patients scoring 1.000 on the EQ-5D comprised 17.3% of the sample at 
baseline and 20.9% at follow-up. 
 
At baseline the Spearman correlation between the EQ-5D and SF-6D was 0.569 and 0.647 at 
follow-up. Both of these correlations were statistically significant (p<0.001). (These 
correlations being significant is to be expected given the relatively large sample size.) 
 
The EQ-5D and SF-6D change scores showed a more modest relationship, with a Spearman 
correlation of 0.366 (p<0.001). The change scores for both the EQ-5D and SF-6D followed a 
symmetrical distribution, but there was a higher level of kurtosis for the EQ-5D (1.72) 
compared to the SF-6D (0.66) due to excess clustering at the mid point (charts not shown). 
 
At baseline the correlation that the BPRS had with the EQ-5D and SF-6D was -0.343 and -
0.314 respectively. There was a modest correlation between the change score on the EQ-5D 
and the BPRS (-0.29). A similar figure was observed for the SF-6D were similar (-0.22 
BPRS). SRMs are shown in Table 3. The EQ-5D and SF-6D had identical scores for patients 
who improved by at least 25% on the BPRS. The figure of 0.39 would usually be interpreted 
as representing a moderate change. For patients who deteriorated by at least 25% the SRM 
was rather less for the EQ-5D. Negligible SRMs were seen for patients having a change of 
less than 25% on the BPRS.  
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Discussion 
 
This is the first study we are aware of that has compared the EQ-5D and SF-6D in patients 
with schizophrenia. Utility scores derived using both approaches were highly correlated and 
mean scores were similar, even though the difference in mean scores at follow-up was 
statistically significant. However, the distributions were very different, with substantially 
higher median scores for the EQ-5D. The SF-6D utility scores followed a normal distribution, 
unlike the EQ-5D which were negatively skewed with a clustering at the maximum score of 
1.000. This may mean that the two instruments are actually measuring different constructs or, 
at the very least, different aspects of quality of life. It was clear from the analysis that there 
was a ceiling effect for the EQ-5D, a finding that has been reported elsewhere [7]. The sample 
consisted of patients with schizophrenia, many of whom had been in contact with services for 
some years and had high levels of disability (shown by the GAF score in Table 1). This 
suggests that the EQ-5D, which indicated 17.3% having maximum quality of life at baseline 
and 20.9% at follow-up, does not reflect the severe nature of schizophrenia. This represents a 
clear limitation of this measure. 
 
There was a significant but small relationship between EQ-5D and SF-6D change scores. The 
change in SF-6D utility scores followed a relatively normal distribution whilst change scores 
for the EQ-5D exhibited a high level of kurtosis. In terms of sensitivity to change in 
symptoms, both measures showed moderate change for patients who improved by at least 
25% on the BPRS; however for those who had a worsening of symptoms, the SF-6D was 
slightly more sensitive. In another study, Stant et al found the EQ-5D to be insensitive to 
change in schizophrenia when compared to other outcome measures, but these did not include 
the SF-6D [1]. 
 - 12 - 
There are a number of limitations to this study. First, the analyses were performed on a pooled 
sample drawn from four European cities. This has the advantage of allowing the analyses to 
be performed on a large sample, but the relationships identified here may differ by site. Whilst 
we had the statistical power to test for site differences we did not do this as we did not wish to 
detract from the central message of the paper. Second, we used UK weights for the EQ-5D 
and SF-6D health states. Again, these may differ by site. Third, change in the BPRS total 
score was compared to change in the EQ-5D and SF-6D but certain subscales may have been 
more appropriate (for example changes in negative symptoms). 
 
In conclusion we have seen that the EQ-5D and SF-6D produce similar mean utility scores in 
patients with schizophrenia. For the purposes of statistical analysis, on the basis of the 
distributions of actual utility scores and change scores the SF-6D has certain advantages. In 
particular, the EQ-5D appears to have a definite ceiling effect. On the basis of this study we 
would – cautiously – recommend the use of the SF-6D out of the two measures but further 
comparisons with the EQ-5D are also required. 
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Table 1. Patient characteristics at baseline. 
 
Characteristics Valid number of cases Mean (sd) 
Age 409 41.5 (11.5) 
Years on medication 366 13.7 (9.9) 
Psychiatric in-patient days in last year 409 27.9 (60.4) 
GAF total score 407 50.3 (13.9) 
  N (%) 
Male 409 245 (59.9%) 
White European 409 310 (75.8%) 
Any psychiatric inpatient admission in last year 409 159 (38.9%) 
 
GAF = Global Assessment of Functioning 
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Table 2. EQ-5D, SF-6D, MANSA and BPRS scores at baseline and follow-up. 
 
 N Mean SD Median Min Max 
EQ-5D baseline 394 0.68 0.29 0.75 -0.35 1.00 
EQ-5D follow-up 368 0.71 0.29 0.80 -0.48 1.00 
EQ-5D change 358 0.04 0.29 0.00 -1.10 0.87 
SF-6D baseline 383 0.67 0.13 0.66 0.32 1.00 
SF-6D follow-up 367 0.68 0.13 0.68 0.30 1.00 
SF-6D change 345 0.01 0.12 0.01 -0.32 0.41 
MANSA baseline 408 4.45 0.98 4.50 1.25 6.75 
MANSA follow-up 370 4.58 0.99 4.63 1.00 7.00 
MANSA change 369 0.12 0.91 0.06 -2.88 3.31 
BPRS baseline 406 45.17 13.02 43.00 24.00 103.00 
BPRS follow-up 371 37.71 10.54 35.00 24.00 84.00 
BPRS change 369 -7.38 12.82 -7.00 -62.00 28.00 
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Table 3. Standardised response mean (SRM)a scores of EQ-5D and SF-6D by level of 
change on BPRS. 
 
BPRS score EQ-5D SF-6D 
Improvement of at least 25% 0.39 
(n=119) 
0.39 
(n=116) 
Deterioration/improvement of less than 25% 0.05 
(n=202) 
0.02 
(n=194) 
Deterioration of at least 25% -0.17 
(n=30) 
-0.27 
(n=29) 
 
a Standardised response mean is defined as the change between baseline and follow-up 
divided by the standard deviation of this change. 
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Figure 1. Distribution of EQ-5D utility scores at baseline. 
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Figure 2. Distribution of SF-6D utility scores at baseline. 
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